Sangui Biotech International (SGBI) 10-Q 14 May 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2020	May 15, 2020
Details
Registrant CIK	0001104280
Fiscal Year End	--06-30
Registrant Name	SANGUI BIOTECH INTERNATIONAL INC
SEC Form	10-Q
Period End date	Mar. 31, 2020
Tax Identification Number (TIN)	84-1330732
Number of common stock shares outstanding		202,729,842
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Document Quarterly Report	true
Entity File Number	0-21271
Entity Address, State or Province	CO
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	Bleichenbrücke 9
Entity Address, Postal Zip Code	20354
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Country Region	49
City Area Code	40
Local Phone Number	46093120
Document Transition Report	false
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Jun. 30, 2019
CURRENT ASSETS
Cash	$ 11,568	$ 27,453
Prepaid expenses and other assets	13,968	9,470
Tax refunds receivable	12,568	6,852
Accounts receivable, net	11,344	29,525
Note receivable, related party	3,428	5,671
Total Current Assets	52,876	78,971
Operating lease right-of-use asset	73,365	0
TOTAL ASSETS	126,241	78,971
LIABILITIES
Accounts payable and accrued expenses	114,843	164,145
Accrued interest - related party	37,577	28,458
Notes payable - related party	565,167	478,357
Operating lease liability -short term	8,381	0
Total Current Liabilities	725,968	670,960
Operating lease liability -long term	64,984	0
Total Liabilities	790,952	670,960
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 202,783,598 and 199,295,503 shares issued and 202,729,842 and 199,241,747 shares outstanding respectively	33,023,316	32,967,499
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	90,318	91,447
Accumulated deficit	(37,627,112)	(37,503,684)
Total Sangui Biotech International, Inc's stockholders' equity (defict)	(19,537)	49,203
Non-controlling interest	(645,174)	(641,192)
Total Stockholders' Deficit	(664,711)	(591,989)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 126,241	$ 78,971

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - shares	Mar. 31, 2020	Jun. 30, 2019
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	202,783,598	199,295,503
Common Stock, Shares, Outstanding	202,729,842	199,241,747

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019
REVENUES
License revenues	$ 9,211	$ 8,062	$ 21,176	$ 63,429
COST OF SALES	0	(99)	0	0
GROSS MARGIN	9,211	8,161	21,176	63,429
OPERATING EXPENSES
Research and development	1,535	5,092	6,421	20,378
Professional fees	35,521	39,700	114,939	142,916
General and administrative	8,590	37,519	28,682	127,920
Depreciation and amortization	1,020	0	1,020	0
Total Operating Expenses	46,666	82,311	151,062	291,214
OPERATING LOSS	(37,455)	(74,150)	(129,886)	(227,785)
OTHER INCOME (EXPENSE)
Loss on out of court settlement	0	0	(6,714)	0
Gain (loss) on foreign exchange	12,838	7,013	19,547	13,470
Interest expense	(3,667)	(2,508)	(10,357)	(8,724)
Total other income (expense)	9,171	4,505	2,476	4,746
LOSS BEFORE INCOME TAXES AND NON-CONTROLLING INTEREST	(28,284)	(69,645)	(127,410)	(223,039)
Provision for income taxes	0	1,481	0	2,694
NET LOSS BEFORE NON-CONTROLLING INTEREST	(28,284)	(71,126)	(127,410)	(225,733)
Less: Net loss attributable to non-controlling interest	1,588	4,713	3,982	13,001
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(26,696)	(66,413)	(123,428)	(212,732)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(1,894)	(3,247)	(1,129)	(4,583)
COMPREHENSIVE LOSS	$ (30,178)	$ (74,373)	$ (128,539)	$ (230,316)
BASIC AND DILUTED LOSS PER SHARE	$ 0	$ 0	$ 0	$ 0
BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	202,308,054	199,295,503	201,313,316	196,410,717

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Treasury Stock	AOCI Including Portion Attributable to Noncontrolling Interest	Noncontrolling Interest	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2018	$ 32,864,356	$ 4,513,328	$ (19,387)	$ 92,921	$ (622,254)	$ (37,180,108)	$ (351,144)
Shares, Outstanding, Beginning Balance at Jun. 30, 2018	191,951,503
Common stock issued for cash	$ 84,491	0	0	0	0	0	84,491
Stock Issued During Period, Shares, New Issues	6,500,000
Currency translation adjustment	$ 0	0	0	(4,583)	0	0	(4,583)
Net loss	0	0	0	0	(13,001)	(212,733)	(225,733)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2019	$ 32,967,499	4,513,328	(19,387)	88,338	(635,255)	(37,392,841)	(478,318)
Shares, Outstanding, Ending Balance at Mar. 31, 2019	199,295,503
Common stock issued for services	$ 18,652	0	0	0	0	0	18,652
Stock Issued During Period, Shares, Issued for Services	844,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2018	$ 32,864,356	4,513,328	(19,387)	92,921	(622,254)	(37,180,108)	(351,144)
Shares, Outstanding, Beginning Balance at Jun. 30, 2018	191,951,503
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2019	$ 32,967,499	4,513,328	(19,387)	91,447	(641,192)	(37,503,684)	(591,989)
Shares, Outstanding, Ending Balance at Jun. 30, 2019	199,295,503
Common stock issued for services							38,048
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2018	$ 32,967,499	4,513,328	(19,387)	91,585	(630,542)	(37,326,426)	(403,943)
Shares, Outstanding, Beginning Balance at Dec. 31, 2018	199,295,503
Common stock issued for cash	$ 0	0	0	0	0	0	0
Currency translation adjustment	0	0	0	(3,247)	0	0	(3,247)
Net loss	0	0	0	0	(4,713)	(66,415)	(71,126)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2019	$ 32,967,499	4,513,328	(19,387)	88,338	(635,255)	(37,392,841)	(478,318)
Shares, Outstanding, Ending Balance at Mar. 31, 2019	199,295,503
Common stock issued for services	$ 0	0	0	0	0	0	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2019	$ 32,967,499	4,513,328	(19,387)	91,447	(641,192)	(37,503,684)	(591,989)
Shares, Outstanding, Beginning Balance at Jun. 30, 2019	199,295,503
Common stock issued for cash	$ 11,055	0	0	0	0	0	$ 11,055
Stock Issued During Period, Shares, New Issues	1,250,000						1,250,000
Common stock issued out of court settlement	$ 44,762	0	0	0	0	0	$ 44,762
Currency translation adjustment	0	0	0	(1,129)	0	0	(1,129)
Net loss	0	0	0	0	(3,982)	(123,428)	(127,410)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2020	$ 33,023,316	4,513,328	(19,387)	90,318	(645,174)	(37,627,112)	(664,711)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	202,783,598
Common stock issued for services							$ 44,762
Common stock issued out of court settlement, Shares	2,238,095
Stock Issued During Period, Shares, Issued for Services							2,238,095
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2019	$ 33,012,261	4,513,328	(19,387)	92,212	(643,586)	(37,600,416)	$ (645,588)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	201,533,598
Common stock issued for cash	$ 11,055	0	0	0	0	0	11,055
Stock Issued During Period, Shares, New Issues	1,250,000
Common stock issued out of court settlement	$ 0	0	0	0	0	0	0
Currency translation adjustment	0	0	0	(1,894)	0	0	(1,894)
Net loss	0	0	0	0	(1,588)	(26,696)	(28,284)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2020	$ 33,023,316	$ 4,513,328	$ (19,387)	$ 90,318	$ (645,174)	$ (37,627,112)	$ (664,711)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	202,783,598

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (127,410)	$ (225,733)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	1,020	0
Common stock issued for services	0	18,652
Loss on out of court settlement	6,714	0
Foreign currency exchange transactions	(19,495)	(13,470)
Amortization of right to use asset	(7,898)	0
Changes in operating assets and liabilities
Trade accounts receivable	17,261	38,125
Prepaid expenses and other current assets	(3,387)	3,910
Tax refunds receivable	(6,021)	(2,010)
Accounts payable and accrued expenses	(9,091)	(65,187)
Related party advances	2,054	2,838
Related party accounts payable	10,202	6,487
Operationg lease liability	7,898	0
Net Cash Used in Operating Activities	(128,153)	(236,388)
Net Cash Provided by (Used in) Investing Activities
Purchase of equipment	(3,102)	0
Net Cash Provided by (Used in) Investing Activities	(3,102)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party note payable	105,222	791,420
Repayment of related party note payable	0	(601,977)
Proceeds from common stock issued for cash	11,055	84,491
Repayment of notes payable	0	(37,796)
Net Cash Provided by Financing Activities	116,277	236,138
EFFECTS OF EXCHANGE RATES ON CASH	(907)	(2,164)
NET CHANGES IN CASH	(15,885)	(2,414)
CASH AT BEGINNING OF PERIOD	27,453	20,943
CASH AT END OF PERIOD	11,568	18,529
CASH FLOW INFORMATION
Interest	0	2,560
Income Taxes	0	0
NON - CASH INVESTING AND FINANCING ACTIVITIES
Right of use operating lease assets obtained in exchange for lease liabilities	81,936	0
Stock issued in settlement of liability	$ 44,762	$ 0

NOTE 1 - BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION	9 Months Ended
	Mar. 31, 2020
Notes
NOTE 1 - BASIS OF PRESENTATION	NOTE 1 - BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2019. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three - and nine-month periods ended March 31, 2020 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2020
Notes
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its 90% owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Hamburg, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Sangui KG is a limited partnership that holds the license rights under the various agreements that the Company enters into from time to time. Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2020 and June 30, 2019 and our unaudited consolidated statements of operations for the three - and nine-month periods ended March 31, 2020 and 2019, were calculated as follows: The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other income. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,627,112 as of March 31, 2020. The Company incurred a net loss before non-controlling interest of $127,410 for the nine - months ended March 31, 2020 and used cash in operating activities of $128,153 during the nine - months ended March 31, 2020. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts. Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred. Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied. Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2020, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive. Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit). Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 3 - COMMITMENTS AND CONTIN

NOTE 3 - COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Mar. 31, 2020
Notes
NOTE 3 - COMMITMENTS AND CONTINGENCIES	NOTE 3 - COMMITMENTS AND CONTINGENCIES Litigation The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a material effect on the Company's financial position or results of operations. At the time of reporting, no litigations are pending. Indemnities and Guarantees During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet. Leases Effective from June 30, 2019 the Company has closed the site in Witten and relocated its headquarters to Hamburg. The Company leases office facilities from an unrelated third party at 1,110 Euros per month, which includes 177 Euros for sales tax. The office lease contract is beginning in January 2020 and expires June 2026. The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month beginning June 2018 expiring May 2020. The following table reconciles future minimum operating lease payments to the discounted lease liability as of June 30, 2019: Minimum Lease Payments Under Operating Leases Office Automobile Total Year ending June 30, 2020 $ 3,073 1,181 4,254 2021 12,291 - 12,291 2022 12,291 - 12,291 2023 12,291 - 12,291 2024 12,291 - 12,291 Thereafter 24,582 - 24,582 Total Operating Lease Obligations $ 76,819 1,181 78,000 Less: Amount representing imputed interest $ (4,632) (3) (4,635) Present Value of minimum lease payments $ 72,187 1,178 73,365 Weighted average discount rate 2% Weighted average remaining term 6.16 years License Agreement Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH respectively Sangui KG and a former contractor, Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG).

NOTE 4 - DEBT

NOTE 4 - DEBT	9 Months Ended
	Mar. 31, 2020
Notes
NOTE 4 - DEBT	NOTE 4 – DEBT Notes Payable Related Parties As of March 31, 2020, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 109,741 5% 26,858 June 30, 2020 December 12, 2017 25,000 27,435 2% 1,263 on demand January 19, 2018 25,000 27,435 2% 1,206 on demand March 13, 2018 25,000 27,435 2% 1,126 on demand July 16, 2018 25,000 27,435 2% 938 on demand September 10, 2018 25,000 27,435 2% 854 on demand October 04, 2018 25,000 27,435 2% 818 on demand December 27, 2018 25,000 27,435 2% 692 on demand January 21, 2019 15,000 16,461 2% 392 on demand February 26, 2019 25,000 27,435 2% 600 on demand March 20, 2019 25,000 27,435 2% 567 on demand April 08, 2019 20,000 21,948 2% 431 on demand May 09, 2019 30,000 32,922 2% 590 on demand June 21, 2019 30,000 32,922 2% 512 on demand September 17, 2019 20,000 21,948 2% 236 on demand October 04, 2019 20,000 21,948 2% 215 on demand October 30, 2019 20,000 21,948 2% 184 on demand January 08, 2020 10,000 10,974 2% 50 on demand February 20, 2020 10,000 10,974 2% 24 on demand March 06, 2020 15,000 16,461 2% 23 on demand On September 17, 2019, on October 04, 2019, on October 30, 2019, on January 08, 2020, on February 20, 2020 and on March 06, 2020 a Company Director advanced amounts totaling 95,000 Euros ($104,254 as of March 31, 2020) to the Company. The loans are due on demand, accrue interest annually at 2% and are unsecured. As of March 31, 2020, the notes have total interest accrued of $732.

NOTE 5 - CAPITAL STOCK

NOTE 5 - CAPITAL STOCK	9 Months Ended
	Mar. 31, 2020
Notes
NOTE 5 - CAPITAL STOCK	NOTE 5 – STOCKHOLDERS’ DEFICT Preferred Stock Common Stock During the nine - months ended March 31, 2020, the Company issued 2,238,095 shares of common stock to one individual for obtaining a settlement in a patent matter at $44,762 ($0.0200 per share). The company recorded an accrual in the amount of $38,048 in the annual financial statements ended June 30, 2019. An additional loss of $6,714 was recorded during the nine - months ended March 31, 2020. During the nine - months ended March 31, 2020, the Company sold 1,250,000 shares of its common stock for approximately $11,055 in cash proceeds to one individual at price of approximately $ 0.009 per share. Treasury Stock Stock – based Compensation

NOTE 6 - SUBSEQUENT EVENTS

NOTE 6 - SUBSEQUENT EVENTS	9 Months Ended
	Mar. 31, 2020
Notes
NOTE 6 - SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS Subsequent to March 31, 2020, a Company Director advanced 25,000 Euros ($28,173) to the Company. The loans are due on demand, accrues interest annually at 2% and are unsecured. In accordance with ASC 855-10, the Company’s management has reviewed all material events and there are no additional material subsequent events to report. In December 2019, COVID-19 emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining of people who may have been exposed to the virus. At the present time, it is not clear how long this crisis will last and what extent it will take. The highest priority for the Company is the health of employees and business partners. The Company is affected by the restrictions currently in place in private and public life around the world to the extent that, the distribution of Granulox wound spray will also be affected. At least for the duration of the restrictions sales activities were not possible due to the worldwide lock downs. In this respect, the company assumes that the license revenue cannot be received at the planned level. The company is in good contact with its licensee. The company and the licensee assume that the desired growth course will be resumed after the pandemic has been overcome. Before the pandemic, the company had essentially been financed through the sale of shares or loans from related parties. These financing options are still available during the COVID-19 - crisis.

NOTE 2 - SUMMARY OF SIGNIFICA_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Consolidation (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Consolidation	Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

NOTE 2 - SUMMARY OF SIGNIFICA_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Foreign Currency Translation	Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2020 and June 30, 2019 and our unaudited consolidated statements of operations for the three - and nine-month periods ended March 31, 2020 and 2019, were calculated as follows: The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other income.

NOTE 2 - SUMMARY OF SIGNIFICA_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,627,112 as of March 31, 2020. The Company incurred a net loss before non-controlling interest of $127,410 for the nine - months ended March 31, 2020 and used cash in operating activities of $128,153 during the nine - months ended March 31, 2020. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2 - SUMMARY OF SIGNIFICA_5

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.

NOTE 2 - SUMMARY OF SIGNIFICA_6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Research and Development	Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.

NOTE 2 - SUMMARY OF SIGNIFICA_7

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied.

NOTE 2 - SUMMARY OF SIGNIFICA_8

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basic and Diluted Loss per Common Share (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Basic and Diluted Loss per Common Share	Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2020, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.

NOTE 2 - SUMMARY OF SIGNIFICA_9

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Comprehensive Loss (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Comprehensive Loss	Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).

NOTE 2 - SUMMARY OF SIGNIFIC_10

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segments of an Enterprise and Related Information (Policies)	9 Months Ended
	Mar. 31, 2020
Policies
Segments of an Enterprise and Related Information	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 3 - COMMITMENTS AND CONT_2

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Tables)	9 Months Ended
	Mar. 31, 2020
Tables/Schedules
Minimum Lease Payments Under Operating Leases	The following table reconciles future minimum operating lease payments to the discounted lease liability as of June 30, 2019: Minimum Lease Payments Under Operating Leases Office Automobile Total Year ending June 30, 2020 $ 3,073 1,181 4,254 2021 12,291 - 12,291 2022 12,291 - 12,291 2023 12,291 - 12,291 2024 12,291 - 12,291 Thereafter 24,582 - 24,582 Total Operating Lease Obligations $ 76,819 1,181 78,000 Less: Amount representing imputed interest $ (4,632) (3) (4,635) Present Value of minimum lease payments $ 72,187 1,178 73,365 Weighted average discount rate 2% Weighted average remaining term 6.16 years

NOTE 4 - DEBT_ Notes Payable Re

NOTE 4 - DEBT: Notes Payable Related Parties (Tables)	9 Months Ended
	Mar. 31, 2020
Tables/Schedules
Notes Payable Related Parties	As of March 31, 2020, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 109,741 5% 26,858 June 30, 2020 December 12, 2017 25,000 27,435 2% 1,263 on demand January 19, 2018 25,000 27,435 2% 1,206 on demand March 13, 2018 25,000 27,435 2% 1,126 on demand July 16, 2018 25,000 27,435 2% 938 on demand September 10, 2018 25,000 27,435 2% 854 on demand October 04, 2018 25,000 27,435 2% 818 on demand December 27, 2018 25,000 27,435 2% 692 on demand January 21, 2019 15,000 16,461 2% 392 on demand February 26, 2019 25,000 27,435 2% 600 on demand March 20, 2019 25,000 27,435 2% 567 on demand April 08, 2019 20,000 21,948 2% 431 on demand May 09, 2019 30,000 32,922 2% 590 on demand June 21, 2019 30,000 32,922 2% 512 on demand September 17, 2019 20,000 21,948 2% 236 on demand October 04, 2019 20,000 21,948 2% 215 on demand October 30, 2019 20,000 21,948 2% 184 on demand January 08, 2020 10,000 10,974 2% 50 on demand February 20, 2020 10,000 10,974 2% 24 on demand March 06, 2020 15,000 16,461 2% 23 on demand

NOTE 2 - SUMMARY OF SIGNIFIC_11

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2020
Sangui BioTech GmbH
Equity Method Investment, Ownership Percentage	90.00%

NOTE 2 - SUMMARY OF SIGNIFIC_12

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019
Details
Accumulated deficit	$ 37,627,112		$ 37,627,112		$ 37,503,684
NET LOSS BEFORE NON-CONTROLLING INTEREST	$ 28,284	$ 71,126	127,410	$ 225,733
Net Cash Used in Operating Activities			$ 128,153	$ 236,388

NOTE 3 - COMMITMENTS AND CONT_3

NOTE 3 - COMMITMENTS AND CONTINGENCIES (Details)	9 Months Ended
	Mar. 31, 2020
Office
Lessee, Operating Lease, Description	The Company leases office facilities from an unrelated third party at 1,110 Euros per month, which includes 177 Euros for sales tax. The office lease contract is beginning in January 2020 and expires June 2026.
Automobile
Lessee, Operating Lease, Description	The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month beginning June 2018 expiring May 2020.

NOTE 3 - COMMITMENTS AND CONT_4

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Details)	9 Months Ended
	Mar. 31, 2020USD ($)
2020	$ 4,254
2021	12,291
2022	12,291
2023	12,291
2024	12,291
Thereafter	24,582
Total Operating Lease Obligations	78,000
Less: Amount representing imputed interest	(4,635)
Present Value of minimum lease payments	73,365
Office
2020	3,073
2021	12,291
2022	12,291
2023	12,291
2024	12,291
Thereafter	24,582
Total Operating Lease Obligations	76,819
Less: Amount representing imputed interest	(4,632)
Present Value of minimum lease payments	$ 72,187
Weighted average discount rate	2.00%
Weighted average remaining terms	6 years 1 month 28 days
Automobile
2020	$ 1,181
2021	0
2022	0
2023	0
2024	0
Thereafter	0
Total Operating Lease Obligations	1,181
Less: Amount representing imputed interest	(3)
Present Value of minimum lease payments	$ 1,178

NOTE 4 - DEBT_ Notes Payable _2

NOTE 4 - DEBT: Notes Payable Related Parties (Details) - USD ($)	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015	Mar. 31, 2020
Interest rate	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Due	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	June 30, 2020
Director
Interest rate																					2.00%
Director | Euro Member Countries, Euro
Loan amount in EURO	$ 15,000	$ 10,000	$ 10,000	$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 20,000	$ 25,000	$ 25,000	$ 15,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 100,000
Director | United States dollar (next day) (funds code)
Loan amount converted into USD	16,461	10,974	10,974	21,948	21,948	21,948	32,922	32,922	21,948	27,435	27,435	16,461	27,435	27,435	27,435	27,435	27,435	27,435	27,435	109,741
Interest in USD	$ 23	$ 24	$ 50	$ 184	$ 215	$ 236	$ 512	$ 590	$ 431	$ 567	$ 600	$ 392	$ 692	$ 818	$ 854	$ 938	$ 1,126	$ 1,206	$ 1,263	$ 26,858

NOTE 4 - DEBT (Details)

NOTE 4 - DEBT (Details) - USD ($)	Mar. 31, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 30, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Accrued interest - related party	$ 37,577							$ 28,458
Interest rate		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Director
Interest rate	2.00%
Director | Principal
Accrued interest - related party	$ 104,254
Director | Interest
Accrued interest - related party	$ 732

NOTE 5 - CAPITAL STOCK (Details

NOTE 5 - CAPITAL STOCK (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019
Preferred Stock, Shares Authorized	10,000,000		10,000,000		10,000,000
Common Stock, Shares Authorized	250,000,000		250,000,000		250,000,000
Common Stock, Shares, Issued	202,783,598		202,783,598		199,295,503
Common Stock, Shares, Outstanding	202,729,842		202,729,842		199,241,747
Stock Issued During Period, Shares, Issued for Services			2,238,095
Common stock issued for services		$ 0	$ 44,762	$ 18,652	$ 38,048
Loss on out of court settlement	$ 0	$ 0	$ 6,714	0
Stock Issued During Period, Shares, New Issues			1,250,000
Proceeds from common stock issued for cash			$ 11,055	$ 84,491
Treasury Stock, Common, Shares	53,756		53,756
Treasury Stock, Value	$ 19,387		$ 19,387
2008 Amended And Restated Long Term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Description			the Board was authorized to issue up to 10,000,000 shares of common stock (including incentive stock options) to certain eligible employees, directors, and consultants of the Company or its subsidiaries. The term of the plan was 10 years. It expired in October 2018.

NOTE 6 - SUBSEQUENT EVENTS (Det

NOTE 6 - SUBSEQUENT EVENTS (Details) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019
Proceeds from related party note payable		$ 105,222	$ 791,420
Subsequent Event
Unusual Risk or Uncertainty, Impact	In December 2019, COVID-19 emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining of people who may have been exposed to the virus. At the present time, it is not clear how long this crisis will last and what extent it will take. The highest priority for the Company is the health of employees and business partners. The Company is affected by the restrictions currently in place in private and public life around the world to the extent that, the distribution of Granulox wound spray will also be affected. At least for the duration of the restrictions sales activities were not possible due to the worldwide lock downs. In this respect, the company assumes that the license revenue cannot be received at the planned level. The company is in good contact with its licensee. The company and the licensee assume that the desired growth course will be resumed after the pandemic has been overcome. Before the pandemic, the company had essentially been financed through the sale of shares or loans from related parties. These financing options are still available during the COVID-19 - crisis.
Director | Subsequent Event
Proceeds from related party note payable	$ 28,173